5 About the SELECT Trial SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) was a multicenter, randomized, double-blind, placebo-controlled, event-driven superiority trial designed to evaluate the efficacy of Wegovy 2.4 mg versus placebo as an adjunct to cardiovascular standard of care for reducing the risk of major adverse cardiovascular events in people with established CVD with overweight or obesity with no prior history of diabetes
It is generally believed that inhibition of K ATP channels by sulfonylureas in pancreatic -cells enables the insulin release to reduce glycemic levels, a primary mechanism underlying pharmacological effectiveness
Within this hierarchy, the gut microbiota act as an integrated modulatory layer rather than a independent predictor
Most patients experience minimal discomfort
The PK-PD disconnect why short half-life doesnt limit efficacy The striking feature of BPC-157 research is the disparity between short serum presence and sustained tissue-level effects
Staying on each new dose for at least four weeks, until reaching an appropriate, therapeutic, maintenance dose of either 5, 10, or 15 mg
